- Home
- LEVI vs JAZZ Comparison
LEVI vs JAZZ Comparison
Compare LEVI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEVI | JAZZ |
|---|---|---|
| Founded | 1853 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.4B |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | LEVI | JAZZ |
|---|---|---|
| Price | $20.38 | $166.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $26.31 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 01-28-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 178.65 | N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $6,282,000,000.00 | $4,157,832,999.00 |
| Revenue This Year | $6.56 | $6.05 |
| Revenue Next Year | $5.12 | $6.23 |
| P/E Ratio | $13.39 | ★ N/A |
| Revenue Growth | ★ 4.14 | 4.14 |
| 52 Week Low | $12.17 | $95.49 |
| 52 Week High | $24.82 | $182.99 |
Technical Indicators
Market Signals| Indicator | LEVI | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 48.69 |
| Support Level | $19.19 | $162.68 |
| Resistance Level | $20.75 | $169.51 |
| Average True Range (ATR) | 0.71 | 4.10 |
| MACD | -0.17 | -0.31 |
| Stochastic Oscillator | 37.46 | 35.03 |
Price Performance
Historical ComparisonAbout LEVI Levi Strauss & Co
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.